Document is current
Any future updates will be listed below
-
Authors
Kizilkaya, Hüsün S. https://orcid.org/0000-0003-2406-9507
Sørensen, Kimmie V. https://orcid.org/0000-0002-3861-4484
Madsen, Jakob S. https://orcid.org/0000-0002-2841-7284
Lindquist, Peter https://orcid.org/0000-0002-8120-3074
Douros, Jonathan D.
Bork-Jensen, Jette
Berghella, Alessandro
Gerlach, Peter A. https://orcid.org/0009-0000-7108-0026
Gasbjerg, Lærke S. https://orcid.org/0000-0002-7880-8515
Mokrosiński, Jacek https://orcid.org/0000-0001-5008-0457
Mowery, Stephanie A.
Knerr, Patrick J.
Finan, Brian https://orcid.org/0000-0002-6467-0447
Campbell, Jonathan E. https://orcid.org/0000-0003-4358-6331
D’Alessio, David A. https://orcid.org/0000-0003-4155-4870
Perez-Tilve, Diego https://orcid.org/0000-0002-0351-4133
Faas, Felix
Mathiasen, Signe
Rungby, Jørgen
Sørensen, Henrik T. https://orcid.org/0000-0003-4299-7040
Vaag, Allan
Nielsen, Jens S. https://orcid.org/0000-0003-3179-1186
Holm, Jens-Christian
Lauenborg, Jeannet https://orcid.org/0000-0002-8485-3793
Damm, Peter https://orcid.org/0000-0002-2067-5246
Pedersen, Oluf https://orcid.org/0000-0002-3321-3972
Linneberg, Allan https://orcid.org/0000-0002-0994-0184
Hartmann, Bolette https://orcid.org/0000-0001-8509-2036
Holst, Jens J. https://orcid.org/0000-0001-6853-3805
Hansen, Torben https://orcid.org/0000-0001-8748-3831
Wright, Shane C. https://orcid.org/0000-0002-7470-5068
Lauschke, Volker M. https://orcid.org/0000-0002-1140-6204
Grarup, Niels https://orcid.org/0000-0001-5526-1070
Hauser, Alexander S. https://orcid.org/0000-0003-1098-6419
Rosenkilde, Mette M. https://orcid.org/0000-0001-9600-3254
-
Funding
Funding for this research was provided by:
European Foundation for the Study of Diabetes
Novo Nordisk Fonden (NNF17SA0031406)
Lundbeckfonden (R278-2018-180, R278-2018-180)
Novo Nordisk Foundation Center for Basic Metabolic Research (NNF18CC0034900, NNF18CC0034900, NNF18CC0034900, NNF18CC0034900, NNF18CC0034900, NNF18CC0034900)
Svenska Läkaresällskapet (PD20-0153)
Robert Bosch Stiftung
- License Information
-
More Information
Article History
Received: 18 April 2023
Accepted: 2 May 2024
First Online: 13 June 2024
Competing interests
: The authors declare that the study was conducted without any commercial or financial relationships that may raise concerns about possible conflicts of interest. L.S.G., J.J.H. and M.M.R. are co-founders and minority shareholders of Antag Therapeutics ApS. J.J.H., B.H. and M.M.R. are co-founders and minority shareholders of Bainan Biotech ApS. M.M.R. is chairman of the board of directors (Bainan Biotech ApS), B.H. is CEO and a member of the board of directors (Bainan Biotech ApS) and J.J.H. is a member of the board of directors of Antag Therapeutics ApS and of Bainan Biotech ApS. V.M.L. is a co-founder, CEO and shareholder of HepaPredict AB, as well as co-founder, CSO and shareholder of Shanghai Hepa Biotechnology Ltd. D.P.-T. maintains research collaborations with Novo Nordisk, MBX Biosciences and BlueWater Biosciences, and is a minority shareholder of BlueWater Biosciences. N.G. is currently employed at Novo Nordisk. J.M. is an employee of Novo Nordisk and J.D.D., S.A.M., P.J.K. and B.F. were formerly employed of Novo Nordisk at the time the work was performed. J.D.D., J.M., S.A.M., P.J.K. and B.F. are shareholders of Novo Nordisk. The remaining authors declare no competing interests.
